UPDATE: BMO Capital Downgrades Pfizer
In a report released Monday, BMO Capital analyst Alex Arfaei downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform while reducing its price target from $34 to $31.
Analysts at BMO stated Pfizer has "limited growth prospects." Pfizer's new drug releases do not outweigh its mature franchises heavily declining dividend; backpacks create some short-term support, but not enough for growth maintenance.
Latest Ratings for PFE
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Morgan Stanley | Maintains | Equal-Weight | |
| Jan 2022 | Wells Fargo | Maintains | Overweight | |
| Jan 2022 | B of A Securities | Upgrades | Neutral | Buy |
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Alex Arfaei BMO CapitalDowngrades Price Target Analyst Ratings
